Project governance

Governing bodies

The Executive Steering Committee (ESC) is common to Ebola+ projects in which Janssen is participating and makes high-level decisions with regards to these Ebola+ projects. The ESC will be chaired by Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).

The Clinical Steering Committee (CSC) is common to EBOVAC1 and EBOVAC2 projects and makes high-level decisions and approvals regarding implementation strategies and dispute resolution for issues arising from the Management Committee (MC). Issues that cannot be resolved by the CSC will be escalated to the ESC. The CSC will be chaired by Janssen.

The EBOVAC2 Management Committee (MC) is in charge of the overall steering (contractual, clinical and scientific) of the project in line with the decisions made by the Clinical Steering Committee, the Executive Steering Committee and the advice provided by the External Advisory Groups. The EBOVAC2 MC will be chaired by Inserm.

Independent advisory boards

Scientific Advisory Boards

The Scientific Advisory Board (SAB) is a consultative body composed of independent inter-disciplinary scientific experts whose role is to provide scientific advice to all projects funded under the Ebola+ programme to ensure maximum impact in scientific, technological and health terms for all concerned parties. The SAB will, where and when relevant, review project deliverables, advise on scientific and technologic choices and for this purpose attend key project events. The SAB will be set up and managed by Inserm with the support of Inserm Transfert (EBOVAC2).

Ethics Board

The Ethics board will have a consultative role in the project and be asked, where and when relevant, to attend project meetings. The final list of sites, the final study protocol, approbation of Ethics Board, and clinical trial registration number will always be provided to IMI2JU. The Ethics Boards will be set up managed by LSHTM (EBOVAC1).


  • Ebovac2 at ECCMID 2019 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 7th EBOVAC2 Newsletter 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • EBOVAC1/2 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • EBOVAC1 consortium reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination - 14th March 2017 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • EBOVAC2 report on BBC News - 8th March 2017 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here :

  • The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016. 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research